The University of Tokyo

Perseus Proteomics Inc.

Aichi Medical University

Institute of Immunology Co., Ltd.

Hiroko Iwanari

Takao Hamakubo

Hiroyuki Aburatani

Isao Kohno

Tatsuhiko Kodama

Masao Ohkuchi

Yasuomi Urano

Taisuke Tomita

Ikuo Hayashi

Takeshi Iwatsubo

Yasuhiro Mochizuki

Yukio Ito

Akira Sugiyama

Takeshi Ito

Yoshinori Murakami

Osamu Arai

Yoshitaka Hippo

Susumu Tokita

Hirokazu Satoh

Hirotaka Itoh

Yutaka Midorikawa

Toshimitsu Momose

Shunsuke Niwa

Shin Ohnishi

Kiyotaka Watanabe

Toshiko Sakihama

Yoshitaka Kumakura

Koji Maemura

Toshiyuki Kitoh

Masahito Tsurusawa

Yoshiko Nakada

Takeshi c/o The University Of Tokyo Iwatsubo

Takao c/o The University Of Tokyo Hamakubo

Taisuke c/o The University Of Tokyo Tomita

Yasuomi Department Of Biotechemistry Dartmouth Medical School Urano

Tatsuhiko c/o The University Of Tokyo Kodama

Koji The University Of Tokyo Maemura

The present invention provides an antibody recognizing a v9 fragment of the cell adhesion molecule CADM1.

CADM1 V9-recognizing antibody

It is an object of the present invention to provide a monoclonal antibody, which is suitable for the quantitative analysis of asparagine synthetase in a cell. The present invention provides a monoclonal antibody which specifically recognizes asparagine synthetase that is present in a cell.

Monoclonal antibody specifically recognizing asparagine synthetase

[Theme] To provide a monoclonal antibody against human GPR87. Also, to provide a novel means for diagnosing or treating a malignant tumor. [Solution means] Monoclonal antibodies against human GPR87 are provided. The antibodies can recognize human GPR87, which is expressed on a cell membrane while retaining a three-dimensional structure, and can recognize GPR87, which is expressed in a cell endogenously with an epitope being present in an extracellular domain of full-length human GPR87. The antibodies are thus useful in biochemical analysis, etc., of GPR87, useful in immunohistological diagnosis, etc., of squamous cell carcinoma, and also potentially useful in PET diagnosis, antibodies for treatment, etc., of squamous cell carcinoma.

Monoclonal antibody, and use thereof

To provide a therapeutic drug for Alzheimer's disease and/or a cancer. The therapeutic drug for Alzheimer's disease and/or a cancer contains an anti-nicastrin antibody, a derivative of the antibody, or a fragment of the antibody or the derivative.

Therapeutic agents for alzheimer's disease and cancer

The present invention provides a novel diagnostic or therapeutic method for pancreatic cancer employing a blood marker. The present invention provides a diagnostic or therapeutic drug for pancreatic cancer containing an anti-AMIGO2 antibody.

Diagnostic agent and therapeutic agent for pancreatic cancer

To provide a method of determining vasculopathy, which is a risk factor of myocardial infarction, angiopathic dementia, etc., at an early stage thereof (i.e., mild vasculopathy). The present invention provides a method of determining the severity of mild vasculopathy, including determining PTX3 level in an assay sample by use of an anti-PTX3 monoclonal antibody.

Method of measuring PTX3 with high sensitivity

It is an object of the present invention to provide a novel antibody capable of specifically recognizing ROBO1 that is expressed in a cell membrane, a hybridoma that produces the above antibody, a method for producing the above antibody, and a tumor diagnostic agent used in PET comprising the above antibody. The present invention provides a monoclonal antibody capable of specifically recognizing ROBO1 existing on the surface of a cell, which is obtained by immunizing an animal to be immunized with a ROBO1-displaying budded baculovirus recovered from the culture supernatant of host cells infected with a recombinant baculovirus comprising the full-length cDNA of ROBO1 as an antigen.

Tumor diagnostic agent used in PET comprising anti-ROBO1 antibody

A method for prognosing possible recurrence after treatment of the liver cancer, characterized by measuring GPC3 contained in a test sample by use of an anti-GPC3 antibody.

Method for predicting and judging the recurrence of liver cancer after treating liver cancer

Growing community of inventors

Shimotuke, Japan

Hiroko Iwanari